Loading...
•
Sep 30, 2023
Sanara MedTech Q3 2023 Earnings Report
Sanara MedTech reported record sales and a narrowed net loss, with positive Adjusted EBITDA.
Key Takeaways
Sanara MedTech Inc. reported a 23% increase in net revenue for the third quarter of 2023, reaching $16.0 million compared to $13.0 million in the same period of the prior year. The company's net loss decreased to $1.1 million from $1.5 million year-over-year. They also completed the acquisition of certain assets related to their collagen business.
Achieved record sales for the quarter.
Net loss narrowed and Adjusted EBITDA was positive.
Completed the acquisition of certain assets related to the collagen business.
Had first sales of ALLOCYTE® Plus and BIASURGE™ after quarter end.
Forward Guidance
Company believes two new products will be important to the future growth plans while helping diversify revenue mix and providing patients and doctors with options that can improve outcomes while reducing healthcare expenditures.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...